PIRAMAL PHARMA LIMITED

BSE: PPLPHARMA543635ISIN INE0DK501011

Healthcare
Pharmaceuticals
BSE 500

Share price

₹237.80+3.95 (+1.69%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹243.10
52W low: ₹132.50
Off 52W high: -2.18%
1M return: +22.01%
3M return: +15.16%
6M return: +44.03%
1Y return: +18.60%
20D avg volume: 7,96,956
50 DMA: ₹209.25
200 DMA: ₹178.04

Key ratios Consolidated

Market cap: ₹31,659 Cr
Current price: ₹237.80
52W high / low: ₹243.10 / ₹132.50
Face value: ₹10.00
P/E: -151.21
P/B: 3.88
EPS (TTM): ₹-1.57
Book value / share: ₹61.29
ROE: —
ROCE: 0.80%
Operating margin: —
Net margin: —
Debt / equity: 0.67
Net debt: ₹4,296 Cr
Interest cover: 0.32
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 112.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	2,617	2,270	2,752	2,140	2,044	1,934	2,754	2,204	2,242	1,951	2,552	1,959
	35.93	89.41	46.06	43.24	65.60	58.40	42.03	12.13	61.11	19.54	26.38	61.51
	2,653	2,359	2,798	2,183	2,109	1,992	2,796	2,216	2,303	1,971	2,579	2,020
	2,589	2,386	2,593	2,246	2,170	2,110	2,540	2,167	2,200	2,038	2,333	1,982
	645.82	724.77	482.59	505.48	483.42	524.35	203.68	805.44	575.14	471.48	400.08	627.63
	335.37	420.24	336.03	376.84	374.83	342.83	546.72	161.06	394.77	314.77	436.06	227.93
	714.32	675.63	586.02	599.85	611.46	618.59	612.01	556.24	559.53	579.69	494.15	523.78
	87.63	88.08	82.99	89.24	82.42	86.15	103.68	103.31	107.64	106.96	114.22	105.88
	233.15	223.55	218.38	212.74	202.84	197.28	242.76	196.81	192.22	184.55	196.13	186.32
	647.82	546.82	649.57	557.98	571.07	514.37	626.09	—	544.14	—	—	—
	63.89	-27.02	205.20	-63.01	-60.97	-118.33	256.58	49.75	102.86	-67.48	245.96	37.68
	0.00	0.00	-175.77	-41.11	0.00	20.74	0.00	0.00	0.00	0.00	-30.52	-32.27
	63.89	-27.02	29.43	-104.12	-60.97	-97.59	256.58	49.75	102.86	-67.48	215.44	5.41
	76.60	61.93	51.83	42.33	53.04	2.68	119.30	63.12	97.53	43.56	126.21	9.25
	5.03	-69.39	-8.82	-136.19	-99.22	-81.70	153.50	3.68	22.59	-88.64	101.27	10.11
	0.04	-0.52	-0.07	-1.03	-0.75	-0.62	1.16	0.03	0.17	-0.67	0.77	0.08
Key metrics
	384.67	284.61	330.80	197.86	224.29	185.84	603.02	349.87	402.72	224.03	525.79	297.61
	14.70%	12.50%	12.00%	9.20%	11.00%	9.60%	21.90%	15.90%	18.00%	11.50%	20.60%	15.20%
	0.20%	-3.10%	-0.30%	-6.40%	-4.90%	-4.20%	5.60%	0.20%	1.00%	-4.50%	4.00%	0.50%
	1.10%	—	0.90%	—	0.20%	—	3.00%	—	—	—	—	—
	28.10%	17.40%	-0.10%	-2.90%	-8.80%	-0.90%	7.90%	12.50%	—	—	—	—
	105.10%	15.10%	-105.70%	-3,800.80%	-539.20%	7.80%	51.60%	-63.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	9,779	8,869	9,151	8,171	7,082
	214.64	213.30	134.81	175.39	225.11
	9,993	9,082	9,286	8,347	7,307
	9,814	9,120	8,944	8,164	7,474
	2,359	1,996	2,056	1,977	1,682
	1,468	1,431	1,417	1,176	952.20
	2,576	2,416	2,307	2,030	1,896
	347.94	340.80	421.59	448.49	344.18
	887.82	831.24	816.34	740.57	676.69
	2,402	2,293	2,167	—	—
	179.06	-37.12	341.71	182.59	-167.52
	-216.88	-196.14	0.00	-62.79	-6.96
	-37.82	-233.26	341.71	119.80	-174.48
	232.69	149.88	323.51	161.47	66.31
	-209.37	-325.94	91.13	17.82	-186.46
	-1.58	-2.46	0.69	0.14	-1.57
Key metrics
	1,198	938.78	1,580	1,309	846.39
	12.25%	10.60%	17.30%	16.00%	12.00%
	-2.14%	-3.70%	1.00%	0.20%	-2.60%
	—	0.80%	6.40%	—	—
	9.43%	-3.10%	12.00%	15.40%	—
	—	-457.70%	411.40%	109.60%	—
	—	762.57	227.92	—	—
	—	-5.07	9.79	—	—
	—	0.67	0.58	—	—
	—	4,296	4,351	—	—
	—	112.9	124.7	—	—
Balance sheet
	—	17,965	15,678	—	—
	—	7,192	5,797	—	—
	—	1,200	368.98	—	—
	—	2,158	2,350	—	—
	—	3,064	2,313	—	—
	—	548.67	551.80	—	—
	—	4,451	4,176	—	—
	—	2,479	1,534	—	—
	—	4,758	3,766	—	—
	—	5,495	4,720	—	—
	—	1,196	1,506	—	—
	—	4,300	3,214	—	—
	—	8,163	8,125	—	—
Cash flow
	—	1,653	892.30	—	—
	—	-826.03	-477.46	—	—
	—	-38.97	-440.83	—	—
	—	890.02	664.38	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,345	1,125	1,489	1,196	1,127	969.88	1,690	1,248	1,284	1,063	1,525	1,024
	137.93	114.63	183.69	96.15	201.97	180.92	39.51	24.70	106.38	36.76	53.19	33.11
	1,483	1,240	1,673	1,292	1,329	1,151	1,729	1,273	1,391	1,100	1,578	1,057
	1,259	1,090	1,275	1,110	1,082	1,008	1,365	1,114	1,115	988.30	1,216	967.59
	353.51	649.70	234.93	347.06	350.95	409.76	336.72	474.23	380.22	405.76	417.52	444.94
	245.30	234.64	194.03	264.03	215.85	192.27	149.93	174.42	232.81	176.44	145.86	171.21
	218.16	216.34	166.55	187.80	188.52	201.95	198.96	173.55	176.72	186.96	152.88	150.56
	17.27	16.36	19.50	16.84	20.38	23.23	30.56	29.17	29.95	24.88	27.66	17.42
	67.56	65.73	70.12	64.69	61.25	59.44	61.17	55.46	53.61	51.85	52.50	51.56
	350.98	297.62	364.95	307.86	355.04	297.44	351.29	—	—	—	—	—
	224.60	149.48	397.42	181.87	247.41	142.58	364.36	159.41	275.71	111.66	362.67	89.66
	0.00	0.00	-65.57	-26.94	0.00	0.00	0.00	—	—	—	—	—
	224.60	149.48	331.85	154.93	247.41	142.58	364.36	159.41	275.71	111.66	362.67	89.66
	53.86	36.00	70.22	26.02	51.08	29.44	87.09	40.61	65.65	26.39	89.59	15.32
	170.74	113.48	261.63	128.91	196.33	113.14	277.27	118.80	210.06	85.27	273.08	74.34
	1.29	0.85	1.97	0.97	1.48	0.85	2.09	0.90	1.59	0.64	2.06	0.56
Key metrics
	309.43	231.57	421.47	236.46	329.04	225.25	456.09	244.04	359.27	188.39	442.83	158.64
	23.00%	20.60%	28.30%	19.80%	29.20%	23.20%	27.00%	19.50%	28.00%	17.70%	29.00%	15.50%
	12.70%	10.10%	17.60%	10.80%	17.40%	11.70%	16.40%	9.50%	16.40%	8.00%	17.90%	7.30%
	2.60%	—	3.90%	—	3.10%	—	4.90%	—	—	—	—	—
	19.30%	16.00%	-11.90%	-4.20%	-12.20%	-8.80%	10.80%	21.90%	—	—	—	—
	-13.00%	0.30%	-5.60%	8.50%	-6.50%	32.70%	1.50%	59.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	5,155	4,782	5,286	4,390	3,443
	532.40	662.73	207.35	202.06	341.07
	5,688	5,445	5,493	4,592	3,784
	4,734	4,475	4,582	4,085	3,654
	1,585	1,343	1,597	1,546	1,166
	938.00	866.18	733.60	624.91	548.69
	788.85	744.82	736.19	613.93	548.50
	69.97	79.95	114.56	107.10	115.87
	268.10	255.50	222.09	205.26	192.08
	1,321	1,325	1,263	—	1,029
	953.37	969.28	911.14	507.62	130.65
	-92.51	-92.51	0.00	—	-6.96
	860.86	876.77	911.14	507.62	123.69
	186.10	176.76	219.74	116.40	54.19
	674.76	700.01	691.40	391.22	69.50
	5.08	5.28	5.22	3.05	0.58
Key metrics
	1,199	1,212	1,248	819.98	431.64
	23.26%	25.30%	23.60%	18.70%	12.50%
	13.09%	14.60%	13.10%	8.90%	2.00%
	—	10.60%	12.70%	—	—
	2.38%	-9.50%	20.40%	27.50%	—
	-4.36%	1.20%	76.70%	462.90%	—
	—	1,031	265.99	—	—
	—	1.90	0.79	—	—
	—	0.09	0.16	—	—
	—	150.86	1,058	—	—
	—	96.8	116.5	—	—
Balance sheet
	—	11,753	10,392	—	—
	—	4,398	3,536	—	—
	—	559.03	163.87	—	—
	—	1,406	1,667	—	—
	—	1,873	1,205	—	—
	—	372.20	391.85	—	—
	—	2,022	2,011	—	—
	—	2,011	1,185	—	—
	—	2,766	2,306	—	—
	—	709.89	1,222	—	—
	—	289.03	865.09	—	—
	—	420.86	356.84	—	—
	—	8,141	7,453	—	—
Cash flow
	—	1,328	548.77	—	—
	—	-317.83	-549.98	—	—
	—	-615.13	-61.74	—	—
	—	297.55	282.78	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +11.57%
Sales CAGR 5Y: —
Profit CAGR 3Y: +115.96%
Profit CAGR 5Y: —
Sales YoY (TTM): +2.38%
Profit YoY (TTM): -4.36%

Consolidated

Sales CAGR 3Y: +7.79%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +9.43%
Profit YoY (TTM): -781.93%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 34.79%

Quarter	September 2026	June 2026
Promoter %	34.79%	34.79%

Holder	Type	Holding	Previous	Change
The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal)	Promoter Group	26.51%	26.51%	0.00%
Ca Alchemy Investments	Public	17.93%	17.93%	0.00%
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund	Public	5.65%	7.68%	-2.03%
V3 Designs LLP	Promoter Group	3.23%	3.23%	0.00%
PRL Realtors LLP	Promoter Group	2.99%	2.99%	0.00%
East Bridge Capital Master Fund I Ltd	Public	2.00%	2.00%	0.00%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	Public	1.56%	—	—
Indiahold Limited	Public	1.30%	1.30%	0.00%
Piramal Welfare Trust	Promoter Group	0.79%	0.79%	0.00%
Semplice Corporate Solutions Private Limited	Promoter Group	0.67%	—	—
The Ajay G Piramal Foundation	Promoter Group	0.33%	0.33%	0.00%
Mr. Anand Piramal	Promoter Group	0.07%	0.07%	0.00%
Anand Piramal Trust	Promoter Group	0.05%	0.05%	0.00%
Mr. Ajay G. Piramal	Promoter	0.04%	0.04%	0.00%
Nandini Piramal Trust	Promoter Group	0.04%	0.04%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund31 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 201530 Oct 2026 · Company Update / Analyst / Investor Meet
Please find enclosed details of Earning call Transcript held on 28th October 2026.30 Oct 2026 · Company Update / Earnings Call Transcript
Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026.28 Oct 2026 · Company Update / Analyst / Investor Meet
Please find enclosed Investor presentation for quarter ended 30 September, 202627 Oct 2026 · Company Update / Investor Presentation
Please find enclosed Press release for quarter ended 30 September, 202627 Oct 2026 · Company Update / Press Release / Media Release
Please find enclosed unaudited financial results for Q2 FY 2727 Oct 2026 · Result / Financial Results
Outcome of Board Meeting of Piramal Pharma Limited held on 27th October, 202627 Oct 2026 · Board Meeting / Outcome of Board Meeting
Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')16 Oct 2026 · Company Update / Analyst / Investor Meet
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....16 Oct 2026 · Board Meeting / Board Meeting
Please refer attachment.1 Oct 2026 · Company Update / General
Please refer attachment.1 Oct 2026 · Company Update / General
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.30 Sep 2026 · Company Update / Change in Management
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.30 Sep 2026 · Company Update / Change in Management
The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....30 Sep 2026 · Company Update / Clarification
Please refer the attachment.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please refer attachment.29 Sep 2026 · Company Update / General
Please refer attached file18 Sep 2026 · Company Update / General
Please refer attached file14 Sep 2026 · Company Update / General
Please refer attached file8 Sep 2026 · Company Update / Analyst / Investor Meet
Please refer attached file3 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please refer attached file24 Aug 2026 · Company Update / General
Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited18 Aug 2026 · Company Update / Acquisition
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited10 Aug 2026 · Company Update / General
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201510 Aug 2026 · Company Update / Analyst / Investor Meet
Please refer attachment3 Aug 2026 · Company Update / General
Please find enclosed details of Earning call Transcript held on 30th July 2026.31 Jul 2026 · Company Update / Earnings Call Transcript
Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM30 Jul 2026 · AGM/EGM / AGM
Proceedings and Voting Results of the 6th Annual General Meeting of the Company30 Jul 2026 · AGM/EGM / AGM
Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.30 Jul 2026 · Company Update / Analyst / Investor Meet
Please see enclosed Investor Presentation for Q1 FY 2729 Jul 2026 · Company Update / Investor Presentation
Please see enlcosed Press Release for Q1 FY 2729 Jul 2026 · Company Update / Press Release / Media Release
Please find enlcosed UFR Q1 FY 27.29 Jul 2026 · Result / Financial Results
Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 202629 Jul 2026 · Board Meeting / Outcome of Board Meeting
Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 202229 Jul 2026 · Company Update / General
Please refer attachment.24 Jul 2026 · Company Update / General
Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.20 Jul 2026 · Company Update / Analyst / Investor Meet
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....20 Jul 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.1400	16 Jul 2025	16 Jul 2025	—
Final Dividend - Rs. - 0.1100	12 Jul 2024	12 Jul 2024	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
29 Jul 2026 Board Meeting - Financial Results